All In Biotech

Drug Trial Radar · NCT06008366

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

A Phase Ⅰ/Ⅱ Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

281

Planned (sponsor's estimate)

Start

Sep 5, 2023

Primary completion

Aug 30, 2025

Study completion Feb 1, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

7MW3711 is an antibody-drug conjugate(ADC) directed to a target wildly expressed on solid tumors. This is an open-label, multicenter, phase 1/2 study to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • 7MW3711 for injectionDrug

    IV administration of 7MW3711, Q3W, 3 weeks a cycle

  • 7MW3711 for injectionDrug

    IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. evaluation of the incidence of adverse events (AEs) (part 1)Time frame: approximately up to 16 cycles, 21 days a cycle
  2. Identification of the MTD and /or RP2D of 7MW3711(part 1)Time frame: from Day1 to Day21 in cycle1 of part 1
  3. Overall response rate (ORR) evaluated by investigators based on RECIST version 1.1 in selected solid tumors(part 2)Time frame: approximately up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ethics Committee of Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.